Tương Tác Dược Phẩm - Dược Động Học với Các Thuốc Kháng Viêm Không Steroid

Mortensen ME, Rennebohm RM. Clinical pharmacology and use of nonsteroidal anti-inflammatory drugs. Pediatr Clin North Am 1989; 36: 1113–39 Knodel LC, Rousch MK, Barton TL. Nonsteroidal anti-inflammatory drugs. Clin Pediatr Med Surg 1992; 9: 301–25 Buchan IE, Bird HA. Drug interactions in arthritic patients. Ann Rheum Dis 1991; 50: 680–1 Hogan DB, Campbell NR, Crutcher R, et al. Prescription of nonsteroidal anti-inflammatory drugs for elderly people in Alberta. Can Med Ass J 1994; 151: 315–22 Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs — differences and similarities. N Engl J Med 1991; 324: 1716–25 Sager DS, Bennett RM. Individualizing the risk/benefit ratio of NSAIDs in older patients. Geriatrics 1992; 47: 24–31 Verbeeck RK. Pharmacokinetic drug interactions with nonsteroidal anti-inflammatory drugs. Clin Pharmacokinet 1990; 19: 44–66 Levy RA, Smith DL. Clinical differences among nonsteroidal antiinflammatory drugs: implications for therapeutic substitution in ambulatory patients. DICP 1989; 23: 76–85 Brater DC. Clinical pharmacology of NSAIDs. J Clin Pharmacol 1988; 28: 518–23 Day RO, Graham GG, Williams KM. Pharmacokinetics of nonsteroidal anti-inflammatory drugs. Baillières Clin Rheumatol 1988; 2: 363–93 Simkin PA, Mary PW, Foster DM. Articular pharmacokinetics of protein-bound antirheumatic agents. Clin Pharmacokinet 1993; 25: 342–50 Patel RB, Shah GF, Jain SM. The effect of rifampicin on piroxicam kinetics. Indian J Physiol Pharmacol 1988; 32: 226–8 Perucca E. Drug interactions with nimesulide. Drugs 1993; 46 Suppl. 1: 79–82 Lapicque F, Muller N, Payan E, et al. Protein binding and stereoselectivity of nonsteroidal anti-inflammatory drugs. Clin Pharmacokinet 1993; 25: 115–25 Pope JE, Anderson JJ, Felson DT. A meta-anaysis of NSAIDs on blood pressure. Arch Intern Med 1993; 22: 477–88 Houston MC. Nonsteroidal anti-inflammatory drugs and anti-hypertensives. Am J Med 1991; 90 (Suppl.): 42S–7S Weinblatt ME. Drug interactions with non steroidal anti-inflammatory drugs (NSAIDS). Scand J Rheumatol 1989; Suppl. 83: 7–10 Shionoiri H. Pharmacokinetic drug interactions with ACE inhibitors. Clin Pharmacokinet 1993; 25: 20–58 Knodel LC. NSAID adverse effects and interactions: who is at risk? Am Pharm 1992; ns32: 39–47 Hardy BG, Bartle WR, Myers M, et al. Effect of indomethacin on the pharmacokinetics and pharmacodynamics of felodipine. Br J Clin Pharmacol 1988; 26: 557–62 Morgan T, Anderson A. Interaction of indomethacin with felodipine and enalapril. J Hypertension 1993; 11 (Suppl 5) 338–9 Verzino E, Kaplan B, Ashley JV, et al. Verapamil-aspirin interaction. Ann Pharmacother 1994; 28: 536–7 Hansten PD. Interaction involving non-steroidal anti-inflammatory drugs. Pharm Int 1984; 5: 300–3 Buckley NA, Dawson AH. Drug interactions with warfarin. Med J Aust 1992; 157: 479–83 Hilleman DE, Mohiuddin SM, Lucas Jr BD. Nonsteroidal anti-inflammatory drug use in patients receiving warfarin: emphasis on nabumetone. Am J Med 1993; 95 Suppl. 2A: 30S–4S Hansten PD. Drug interactions and updates quarterly. Applied Therapeutics Inc. Vancouver 1993; 13(3): 57–63 Kearon C, Hirsch J. Optimal dose for starting and maintaining low dose aspirin. Arch Intern Med 1993; 153: 700–2 Second International Study of Infarct Survival Collaborative Group (ISIS 2). Randomized trial of intravenous streptokinase, oral aspirin, both or neither among cases of suspected acute myocardial infarction. Lancet 1988; 2: 349–60 The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827–30 Bang CJ, Riedel B, Talstad I, et al. Interaction between heparin and acetylsalicylic acid on gastric mucosal and skin bleeding in humans. Scand J Gastroenterol 1992; 27: 489–94 Weale A, Warwick D, Durant N. Is there haemostatic interaction between low molecular-weight heparin and non steroidal analgesics after total hip replacement? [letter]. Lancet 1993; 342: 995 Updating Ketorolac. Inpharma 1994 Jan 22; 921: 21 Williams KM, Day RO. The contribution of enantiomers to variability in response to anti inflammatory drugs. Agents Actions 1988; 24: 76–8 Furst DE. Clinically important interactions of nonsteroidal anti-inflammatory drugs with other medications. J Rheumatol Suppl 1988; 15 Suppl. 17: 58–62 Brouwers JRBJ. Drug interactions with quinolones antibacterials. Drug Saf 1992; 4: 268–81 Rollof J, Vinge E. Neurologic adverse effects during concomitant treatment with ciprofloxacin, NSAIDs, and chloroquine: possible drug interaction. Ann Pharmacother 1993; 27: 1058–9 Sheiner PA, Mor E, Chodoff L, et al. Acute renal failure associated with the use of ibuprofen in two liver transplant recipients on FK506. Transplantation 1994; 57: 1132–3 McInnes GT, Brodie MJ. Drug interactions that matter: a critical reappraisal. Drugs 1988; 36: 83–110 Hansten PD, Horn JR. All nonsteroidal anti-inflammatory drugs are not alike with regard to drug interactions. Drug Int News 1987; 7: 7–12 Bush TM, Shlotzhauer TL, Imai K. Nonsteroidal anti-inflammatory drugs, proposed guidelines for monitoring toxicity. West J Med 1991; 155: 39–42 Gugler R, Allgayer H. Effects of antacids on the clinical pharmacokinetics of drugs: an update. Clin Pharmacokinet 1990; 18: 210–9 Miners JO. Drug interactions involving aspirin (acetylsalicylic acid) and salicylic acid. Clin Pharmacokinet 1989; 17: 327–44 Gaspari F, Viganò G, Locatelli M, et al. Influence of antacid administrations on aspirin absorption in patients with chronic renal failure on maintenance hemodialysis. Am J Kidney Dis 1988; 11: 338–42 Gontarz N, Small RE, Comstock TJ, et al. Effect of antacid suspension on the pharmacokinetics of ibuprofen. Clin Pharm 1987; 6: 413–6 Caillé G, Souich du P, Vézina M, et al. Pharmacokinetic interaction between flurbiprofen and antacids in healthy volunteers. Biopharm Drug Dispos 1989; 10: 607–15 Brocks DR, Jamali F. Clinical pharmacokinetics of ketorolac tromethamine. Clin Pharmacokinet 1992; 23: 415–27 Veys EM. 20 years’ experience with ketoprofen. Scand J Rheumatol 1991; Suppl. 90: 1–44 Jamali F, Brocks DR. Clinical pharmacokinetics of ketoprofen and its enantiomers. Clin Pharmacokinet 1990; 19(3): 199–217 Gonzalez JP, Todd PA. Tenoxicam: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1987; 34: 289–310 Güntert TW, Heintz RC, Joly R. Overview on the pharmacokinetics of tenoxicam. Eur J Rheumatol Inflamm 1987; 9: 15–25 Francis RJ, Dixon JS, Lowe JR, et al. The effects of food and antacid on the single oral dose pharmacokinetics of tenoxicam. Eur J Drug Metabol Pharmacokinet 1985; 10: 309–14 Ravic M, Johnston A, Turner A. Clinical pharmacological studies of some possible interactions of lornoxicam with other drugs. Postgrad Med J 1990; 66 Suppl. 4: S30–4 Dittrich P, Radhofer-Welte S, Magometschnigg D, et al. The effect of concomitantly administered antacids on the bioavailability of lornoxicam, a novel highly potent NSAID. Drugs Exp Clin Res 1990; 16: 57–62 Neuvonen PJ, Kivistö KT. Effect of magnesium hydroxide on the absorption of tolfenamic and mefenamic acid. Eur J Pharmacol 1988; 35: 495–501 Nunes D, Kennedy NP, Weir DG. Treatment of peptic ulcer disease in the arthritic patient. Drugs 1989; 38(3): 451–61 Rainsford KD, James C, Hunt RH, et al. Effects of misoprostol on the pharmacokinetics of indomethacin in human volunteers. Clin Pharmacol Ther 1992; 51: 415–21 Caille G, Souich du P, Gervais P, et al. Effects of concurrent sucralfate administration on pharmacokinetics of naproxen. Am J Med 1987; 83 Suppl. 3B: 67–73 Caillé G, Souich du P, Besner JG, et al. Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. Am J Med 1989; 86 Suppl. 6A: 38–44 Lafontaine D, Mailhot C, Vermeulen M, et al. Influence of chewable sucralfate or a standard meal on the bioavailability of naproxen. Clin Pharm 1990; 9: 773–7 Ungethüm W. Study on the interaction between sucralfate and diclofenac/piroxicam in healthy volunteers. Arzneimittelforschung 1991; 41: 797–800 Anaya AL, Mayersohn M, Conrad KA, et al. The influence of sucralfate on ibuprofen absorption in healthy adult males. Biopharm Drug Dispos 1986; 7: 443–51 Li SP, Pendharkar CM, Mehta GN, et al. Sucralfate has a bioadhesive gastric intestinal retention system: preliminary evaluation. Drug Dev Indust Pharm 1993; 19: 2519–37 Rainsford KD. NSAID gastropathy novel physicochemical approaches of reducing gastric mucosal injury by drug complexation with cyclodextrins. Drug Invest 1990; 2 Suppl. 4: 3–10 Ravic M, Johnston A, Turner P, et al. Does bismuth chelate influence lornoxicam absorption? Hum Exp Toxicol 1992; 11: 59–61 De Bernardi di Valserra M, Feletti F, Bertè F, et al. Lack of effect of a single-dose of sulglicotide on the bioavailability of diclofenac. Eur J Clin Pharmacol 1988; 34: 211–2 Karim A. Pharmacokinetics of diclofenac and misoprostol when administered alone or as a combination product. Drugs 1993; 45 Suppl. 1: 7–14 Siegmund W, Scheuch E, Zschiesche M, et al. Potential pharmacokinetic interactions of nocloprost clathrate with retarded theophylline and enteric coated diclofenac after single and repeated premedication in healthy volunteers. Int J Clin Pharmacol Ther Toxicol 1993; 31: 407–14 Siegmund W, Zschiesche M, Franke G, et al. Effects of nocloprost clathrate on absorption of acetylsalicylic acid. Int J Clin Pharmacol Ther 1994; 32: 51–7 Hsyu PH, Cox JW, Pullen RH, et al. Pharmacokinetic interactions between arbaprostil and aspirin in humans. Biopharm Drug Dispos 1989; 10: 411–22 Dixon JS, Page MC. Interactions between non-steroidal anti-inflammatory drugs and H2-receptor antagonists or prostaglandin analogues. Rheumatol Int 1991; 11: 13–8 Simon B, Damman HG, Leucht U, et al. Ranitidine in the therapy of NSAID-induced gastroduodenal lesions. Scand J Gastroenterol 1988; 23 Suppl. 154: 18–22 Penston JG, Wormsley KG. Ranitidine maintenance treatment of non-steroidal anti-inflammatory drug-induced duodenal ulceration. Aliment Pharmacol Ther 1989; 3: 499–503 Aabakken L, Bjornbeth BA, Weberg R, et al. NSAID-associated gastroduodenal damage: does famotidine protection extend into the mid- and distal duodenum? Aliment Pharmacol Ther 1990; 4: 295–303 Bank S, Greenberg RE, Magier D, et al. The efficacy and tolerability of famotidine and ranitidine on the healing of active duodenal ulcer and during six month maintenance treatment, with special reference to NSAID/aspirin-related ulcers. Clin Ther 1991; 13: 304–18 Howden CW. Review: interactions between H2-antagonists and non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 1988; 2: 93–100 Klotz U, Kroemer HK. The drug interaction potential of ranitidine: an update. Pharmacol Ther 1991; 50: 233–44 Dixon JS, Lacey LF, Pickup ME, et al. A lack of pharmacokinetic interaction between ranitidine and piroxicam. Eur J Clin Pharmacol 1990; 39: 583–6 Delhotel-Landes B, Flouvat B, Liote F, et al. Pharmacokinetic interactions between NSAIDs (indomethacin or sulindac) and H2-receptor antagonists (cimetidine or ranitidine) in human volunteers. Clin Pharmacol Ther 1988; 44(4): 442–52 Said SA, Foda AM. Influence of cimetidine on the pharmacokinetics of piroxicam in rat and man. Arzneimittelforschung 1989; 39: 790–2 Milligan PA, McGill PE, Howden CW, et al. The consequences of H2 receptor antagonist-piroxicam coadministration in patients with joint disorders. Eur J Clin Pharmacol 1993; 45: 507–12 Forsyth DR, Jayasinghe KSA, Roberts CJC. Do nizatidine and cimetidine interact with ibuprofen? Eur J Clin Pharmacol 1988; 35: 85–8 Evans AM, Nation RL, Sansom LN. Lack of effect of cimetidine on the pharmacokinetics of R-(−) and S-(+) ibuprofen. Br J Clin Pharmacol 1989; 28: 143–9 Small RE, Cox SR, Adams WJ. Influence of H2-receptor antagonists on the disposition of flurbiprofen enantiomers. J Clin Pharmacol 1990; 30: 660–4 Kendall MJ, Gibson R, Walt RP. Coadministration of misoprostol or ranitidine with indomethacin: effects on pharmacokinetics, abdominal symptoms and bowel habit. Aliment Pharmacol Ther 1992; 6: 437–46 Verbeeck RK, Corman CL, Wallace SM, et al. Single and multiple dose pharmacokinetics of enteric coated ketoprofen: effect of cimetidine. Eur J Clin Pharmacol 1988; 35: 521–7 Day RO, Geisslinger G, Paull P, et al. Neither cimetidine nor probenecid affect the pharmacokinetics of tenoxicam in normal volunteers. Br J Clin Pharmacol 1994; 37: 79–81 Vree TB, van den Biggelaar-Martea M, Verwey-van Wissen CP, et al. The effects of cimetidine, ranitidine and famotidine on the single-dose pharmacokinetics of naproxen and its metabolites in humans. Int J Clin Pharmacol Ther Toxicol 1993; 31: 597–601 Ravic M, Salas-Herrera I, Johnston A, et al. A pharmacokinetic interaction between cimetidine or ranitidine and lornoxicam. Postgrad Med J 1993; 69: 865–6 Stockley IH. Drug interactions: a source book of adverse interactions, their mechanisms, clinical importance and management. 2nd ed. Oxford: Blackwell, 1991 Guentert TW, Defoin R, Mosberg H. The influence of cholestyramine on the elimination of tenoxicam and piroxicam. Eur J Clin Pharmacol 1988; 34: 283–9 Vree TB, Van den Biggelaar-Martea M, Verwey-van Wissen CPWGM, et al. Probenecid inhibits the glucuronidation of indomethacin and O-desmethylindomethacin in humans. Pharm Word Sci 1994; 16: 22–6 Spahn H, Spahn I, Benet LZ. Probenecid-induced changes in the clearance of carprofen enantiomers: a preliminary study. Clin Pharmacol Ther 1989; 45: 500–5 MacDonald JL, Herman RJ, Verbeeck RK. Sex difference and the effects of smoking and oral contraceptive steroids on the kinetics of diflunisal. Eur J Clin Pharmacol 1990; 38: 175–9 Scavone JM, Ochs HR, Greenblatt DJ, et al. Pharmacokinetics of oxaprozin in women receiving conjugated estrogen. Eur J Clin Pharmacol 1988; 35: 105–8 Edelman J, Potter JM, Hacket JP. The effect of intra-articular steroids on plasma salicylate concentrations. Br J Clin Pharmacol 1986; 21: 301–7 Koren G, Roifman C, Gelfand E, et al. Corticosteroids-salicylate interaction in a case of juvenile rheumatoid arthritis. Ther Drug Monit 1987; 9: 177–9 Derendorf H, Mullersman G, Barth J, et al. Pharmacokinetics of diclofenac sodium after intramuscular administration in combination with triamcinolone acetate. Eur J Clin Pharmacol 1986; 31: 363–5 Spahn H, Langguth P, Kirch W, et al. Pharmacokinetics of salicylates administered with metoprolol. Arzneimittelforschung 1986; 36: 1697–9 Sommers DK, Kovarik JM, Meyer EC, et al. Effects of diclofenac on isradipine pharmacokinetics and platelet aggregation in volunteers. Eur J Clin Pharmacol 1993; 44: 391–3 Seideman P. Lack of effect of paracetamol on the pharmacokinetics of indomethacin and paracetamol in humans. J Clin Pharmacol 1991; 31: 804–7 O’Reilly RA. Warfarin metabolism and drug-drug interactions. Adv Exp Med Biol 1987; 214: 205–12 Win N, Mitchell DC. Azapropazone and warfarin [letter]. BMJ 1991; 302: 969 Tonkin AL, Wing LMH. Interactions of non-steroidal anti-inflammatory drugs. Baillières Clin Rheumatol 1988; 2: 455–83 Jain A. Effect of naproxen on the steady state serum concentration and anticoagulant action of warfarin. Clin Pharmacol Ther 1979; 25: 61–5 Ermer JC, Hicks DR, Wheeler SC, et al. Concomitant etodolac affects neither the unbound clearance nor the pharmacologic effect of warfarin. Clin Pharmacol Ther 1994; 55: 305–16 Pullar T. Interaction of ibuprofen and warfarin on primary haemostasis. Br J Rheumatol 1989; 28: 265–6 Mieszczak C, Winther K. Lack of interaction of ketoprofen with warfarin. Eur J Clin Pharmacol 1993; 44: 205–6 Flessner MF, Knight H. Prolongation of prothrombin time and severe gastrointestinal bleeding associated with combined use of warfarin and ketoprofen [letter]. JAMA 1988; 259: 353 Toon S, Holt BL, Mullins FGP, et al. Investigation into the potential effects of multiple dose ketorolac on the pharmacokinetics and pharmacodynamics of racemic warfarin. Br J Clin Pharmacol 1990; 30: 743–50 Ravic M, Johnston A, Turner P, et al. A study of the interaction between lornoxicam and warfarin in healthy volunteers. Hum Exp Toxicol 1990; 9: 413–4 Todd PA, Brogden RN. Oxaprozin: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1986; 32: 291–312 Eichler HG, Jung M, Kyrle PA, et al. Absence of interaction between tenoxicam and warfarin. Eur J Clin Pharmacol 1992; 42: 227–9 Whittaker SJ, Jackson CW, Whorwell PJ. A severe, potentially fatal, interaction between tiaprofenic acid and nicoumalone [letter]. Br J Clin Pract 1986; 40: 440 Koren JF, Cochran DL. Tolmetin-warfarin interaction. Am J Med 1987; 82: 1278–80 Chan TY, Lui SF, Chung SY, et al. Adverse interaction between warfarin and indomethacin. Drug Saf 1994; 10: 267–9 Chow WH, Cheung KL, Ling HM, et al. Potentiation of warfarin anticoagulation by topical methylsalicylate ointment. J R Soc Med 1989; 82: 501–2 Yip ASB, Chow WH, Tai YT, et al. Adverse effect of topical methylsalicylate ointment on warfarin anticoagulation: an unrecognized potential hazard. Postgrad Med J 1990; 66: 367–9 Choonara I, Cholerton S, Haynes BP, et al. Stereoselective interaction between the R-enantiomer of warfarin and cimetidine. Br J Clin Pharmacol 1986; 21: 271–7 Carcia B, Lacambra C, Garrote F, et al. Possible potentiation of anticoagulant effect of acenocoumarol by omeprazole. Pharm World Sci 1994; 16: 231–2 Schwartz A, Seoka SNE. Potential aspirin-related drug interactions in the elderly. DICP 1989; 23: 340–4 Tornvall G, Aligen BLG. Acute effects of acetylsalicylic acid on blood glucose and insulin in non-insulin dependant diabetes. Acta Endocrinol 1980; 239: 6–8 Speders von S. Mofebutazon-Prüfung einer möglichen Interaktion mit Glibenclamid. Fortschr Med 1993: 23; 366–8 Pisani F. Influence of co-medication on the metabolism of valproate. Pharm Weekbl Sci 1992; 14: 108–13 Goulden KJ, Dooley JM, Camfield PR, et al. Clinical valproate toxicity induced by acetylsalicylic acid. Neurology 1987; 37: 1392–4 Rodin SM, Johnson BE Pharmacokinetic interactions with digoxin. Clin Pharmacokinet 1988; 15: 239–40 Jörgensen HS, Christensen HR, Kampmann JP. Interaction between digoxin and indomethacin or ibuprofen. Br J Clin Pharmacol 1991; 31: 108–10 Baggio E, Maraffi F, Montalto C, et al. A clinical assessment of the potential for pharmacological interaction between nimesulide and digoxin in patients with heart failure. Drugs 1993; 46 (Suppl1): 91–4 Haig GM, Brookfield EG. Increase in serum digoxin concentrations after indomethacin therapy in a full-term neonate. Pharmacotherapy 1992; 12: 334–6 Ragheb M. The clinical significance of lithium-nonsteroidal anti-inflammatory drug interactions. J Clin Psychopharmacol 1990; 10: 350–4 Harvey NS. Lithium intoxication [letter]. BMJ 1991; 302: 1537 McDonald J, Neale TJ. Toxic interaction of lithium carbonate and mefenamic acid [letter]. BMJ 1988; 297: 1339 Shelley RK. Lithium toxicity and mefenamic acid. Br J Psychiatry 1987; 151: 847–8 Langlois R, Paquette D. Increased serum lithium levels due to ketorolac therapy. Can Med Ass J 1994; 150: 1455–6 Seifert CF, Stanaszek WE Arthritis in the elderly: update 1990. J Geriatr Drug Ther 1990; 4: 7–41 Bahnwarth B, Labat L, Moride Y, et al. Methotrexate in rheumatoid arthritis: an update. Drugs 1994; 47: 25–50 Luqmani R, Gordon C, Bacon P. Clinical pharmacology and modification of auto immunity and inflammation in rheumatoid disease. Drugs 1994; 47: 259–85 Slordal L, Sager G, Aarbakke J. Pharmacokinetic interactions with methotrexate: is 7-hydroxy-methotrexate the culprit? Lancet 1988; 1: 591–2 Thyss A, Kubaz J, Milano G. Clinical and pharmacokinetic evidence of life threatening interaction between methotrexate and ketoprofen. Lancet 1986; 1: 256–8 Rooney TW, Furst DE. Comparison of toxicity in methotrexate (MTX) treated RA patients also taking aspirin or other NSAIDs [abstract]. Arthritis Rheum 1986; 26 (Suppl.): S579 Stewart CF, Evans WE. Drug-drug interactions with antirheumatic agents: review of selected clinically important interactions. J Rheumatol Suppl 1990; 17 Suppl. 22: 16–23 Skeith KJ, Russel AS, Jamali F, et al. Lack of significant interaction between low dose methotrexate and ibuprofen in patients with arthritis. J Rheumatol 1990; 17(8): 1008–10 Anaya JM, Fabre D, Bressolle F, et al. Effect of etodolac on methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Rheumatol 1994; 21: 203–8 Furst DE, Herman RA, Koehnke R, et al. Effect of aspirin and sulindac on methotrexate clearance. J Pharm Sci 1990; 79: 782–6 Raveendran R, Heybroek W, Caulfield M, et al. Indomethacin and protein binding of methotrexate. Hum Exp Toxicol 1992; 11: 291–3 Tracy TS, Krohn K, Jones DR, et al. The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis. Eur J Clin Pharmacol 1992; 42: 121–5 Dupuis LL, Koren G, Shore A, et al. Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. J Rheumatol 1990; 17(11): 1469–94 Wallace CA, Smith AL, Sherry DD. Pilot investigation of naproxen/methotrexate interaction in patients with juvenile rheumatoid arthritis. J Rheumatol 1993; 20: 1764–8 Ahern M, Booth J, Loxton A, et al. Methotrexate kinetics in rheumatoid arthritis: is there an interaction with nonsteroidal antiinflammatory drugs. J Rheumatol 1988; 15(9): 1356–60 Zachariae H. Methotrexate and non-steroidal anti-inflammatory drugs. Br J Dermatol 1992; 126: 95–8 Frenia ML, Long KS. Methotrexate and nonsteroidal anti-inflammatory drug interactions. Ann Pharmacother 1992; 26: 234–7 Dijkmans BAC, Rijthoven van AWAM, Goei de HS. Cyclosporine in rheumatoid arthritis. Semin Arthritis Rheum 1992; 22: 30–6 Prescot LF, Martin U. Current status of nephrotoxicity caused by NSAIDs. In: Rainsford KD, Velo GP, editors. Side effects of anti-inflammatory drugs 3. (Series Inflammation and drug therapy vol.5) Dordrecht: Kluwer Publ, 1992: 223–36. Grillas J. Nephrotoxicity potential with cyclosporin and nonsteroidal anti-inflammatory drugs. Aust J Hosp Pharm 1989; 19: 244–5 Kovarik JM, Mueller EA, Gaber M, et al. Pharmacokinetics of cyclosporin and steady-state aspirin during co-administration. J Clin Pharmacol 1993; 33: 513–21 Altman RD, Perez GO, Sfakianakis GN. Interaction of cyclosporine A and nonsteroidal anti-inflammatory drugs on renal function in patients with rheumatoid arthritis. Am J Med 1992; 93: 396–402 Mueller EA, Kovarik JM, Koelle EU, et al. Pharmacokinetics of cyclosporine and multiple-dose diclofenac during coadministration. J Clin Pharmacol 1993; 33: 936–43 Agar JWMcD. Cyclosporin A and mefenamic acid in a renal transplant patient. Aust NZ J Med 1991; 21: 784–5 Deray G, Hoang Le P, Aupetit B, et al. Enhancement of cyclosporine A nephrotoxicity by diclofenac. Clin Nephrol 1987; 27: 213–4 Sesin GP, O’Keefe E, Roberto P. Sulindac-induced elevation of serum cyclosporine concentration. Clin Pharm 1989: 8; 445–6 Branthwaite JP, Nicholls A. Cyclosporin and diclofenac interaction in rheumatoid arthritis [letter]. Lancet 1991; 337: 252 Harris KP, Jenkins D, Walls J. Nonsteroidal antiinflammatory drugs and cyclosporine. Transplantation 1988; 46: 598–9 Ludwin D, Bennett KJ, Grace EM, et al. Nephrotoxicity in patients with rheumatoid arthritis treated with cyclosporine. Transplant Proc 1988; 20 Suppl. 4: 367–70 Jerome M, Davis JC. The effects of indomethacin on gentamicin serum levels. Proc West Pharmacol Soc 1987; 30: 85–7 Halliwell RF, Davey PG, Lambert JJ. Antagonism of GABAa receptors by fluoroquinolones. J Antimicrob Chemother 1993; 31: 457–62 Kawakami J, Shimokawa M, Yamamoto K, et al. Inhibition of GABAa receptor-mediated current responses by enoxacin and felbinac in Xenopus oocytes injected with mouse brain messenger RNA. Biol Pharm Bull 1993; 16: 726–8 Fillastre JP, Leroy A, Borsa-Lebas F, et al. Effects of ketoprofen on the pharmacokinetics of pefloxacin and ofloxacin in healthy volunteers. Drugs Exp Clin Res 1992; 18: 487–92 Leroy A, Borsa-Lebas F, Fillastre JP, et al. Influence du kétoprofène sur la pharmacocenétique de deux fluoroquinolones chez l’homme. Pathol Biol 1993; 41: 379–84 Burger DM, Meenhorst PL, Koks CHW, et al. Drug interactions with zidovudine. AIDS 1993; 7: 445–60 Sim SM, Back DJ, Breckenridge AM. The effect of various drugs on the glucuronidation of zidovudine (azidothymidine; AZT) by human liver microsomes. Br J Clin Pharmacol 1991; 32: 17–21 Sahai J, Gallicano K, Garber G, et al. Evaluation of the in vivo effect of naproxen on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. Clin Pharmacol Ther 1992; 52: 464–70 Sweeney KR, Chapron DJ, Brandt JL. Toxic interaction between acetazolamide and salicylate: case reports and a pharmacokinetic explanation. Clin Pharmacol Ther 1986; 40: 518–24 Sweeney KR, Chapron DJ, Antal EJ, et al. Differential effects of flurbiprofen and aspirin on acetazolamide disposition in humans. Br J Clin Pharmacol 1989; 27: 866–9 Spahn H, Langguth P, Krauss D, et al. Pharmacokinetics of atenolol and metoprolol administered together with piroxicam. Arch Pharm (Weinheim) 1987; 320: 103–7 Raina RK, Bano G, Amla V, et al. The effect of aspirin, paracetamol and Analgin on pharmacokinetics of chloroquine. Indian J Physiol Pharmacol 1993; 37: 229–31 Rollof J, Vinge E. Neurologic adverse effects during concomitant treatment with ciprofloxacin, nsaids, and chloroquine: possible drug interaction. Ann Pharmacother 1993; 27: 1058–9 Cosolo W, Schwarz MA, Christophidis N, et al. Interaction of cisplatin with other cytotoxic and non-steroidal anti-inflammatory drugs. Anticancer Drugs 1991; 2: 169–74 Carrero E, Castillo J, Bogdanovich A, et al. El diclofenaco no modifica las caracteristicas de la induccion anesthesica con midazolam. Rev Esp Anesthesiol Reanim 1993; 40: 238–40 Conno De F, Ripamonti C, Bianchi M, et al. Diclofenac does not modify morphine bioavailability in cancer patients. Pain 1993; 55: 401–2 Jain PN, Shah SC. Respiratory depression following combination of epidural buprenorphine and intramuscular ketorolac. Anaesthesia 1993; 48: 898–9 Garg V, Blum R, Wilner KD, et al. Effect of the anti-inflammatory agent tenidap on the pharmacokinetics and pharmacodynamics of prednisolone. J Clin Pharmacol 1992; 32: 222–30 Zacharieva S, Wippermann M, Mucha I, et al. Indomethacin and meclofenamate do not alter ACTH and cortisol responses to corticotropin-releasing hormone (CRH) in normal subjects. Clin Physiol Biochem 1993; 10: 28–32 Daigneault EA, Hamdy RC, Ferslew KE, et al. Investigation of the influence of acetylsalicylic acid on the steady state of long-term therapy with theophylline in elderly male patients with normal renal function. J Clin Pharmacol 1994; 34: 86–90 Ripley EB, Gehr TW, Wallace H, et al. The effect of nonsteroidal agents (NSAIDs) on the pharmacokinetics and pharmacodynamics of metolazone. Int J Clin Pharmacol Therap 1994; 32: 12–8 Grace EM, Mewa AAM, Sweeney GD, et al. Lowering of plasma isoxicam concentrations with acetylsalicylic acid. J Rheumatol 1986; 13: 1119–21 Esquival M, Cussenot F, Olgilvre RI, et al. Interaction of isoxicam with salicylic acid. Br J Clin Pharmacol 1984; 18: 567–71 Furst DE, Sarkissian E, Blocka K, et al. Serum concentrations of salicylate and naproxen during concurrent therapy in patients with rheumatoid arthritis. Arthritis Rheum 1987; 30: 1157–61 Eriksson LO, Wählin-Boll E, Liedholm H, et al. Influence of chronic diflunisal treatment on the plasma levels, metabolism and excretion of indomethacin. Eur J Clin Pharmacol 1989; 37: 7–15 van Hecken A, Verbesselt R, Tjandra-Maga TB, et al. Pharmacokinetic interaction between indomethacin and diflunisal. Eur J Clin Pharmacol 1989; 3: 507–12 Roth SH. A controlled study comparing the effects of nabumetone, ibuprofen and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa. Arch Intern Med 1993; 153: 2565–71